Insider · CIK 0001625110

Dorval Allison

Reports to the SEC for 5 companies · LOS ANGELES, CA

sec.gov

Transactions

Companies

Filings

CIK

0001625110

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-12	PBYIPUMA BIOTECHNOLOGY, INC.S Sale	Director	SSale	−11.6K sh	$7.20	−$83.6K	90,780
2026-06-11	PBYIPUMA BIOTECHNOLOGY, INC.A Award	Director	AAward	+27K sh	—	—	102,390
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−258K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−75K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−45K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−180K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.U Disposition from Tender	Chief Financial Officer	UDisposition from Tender	−13.3K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−33.8K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−1,875 sh	—	—	0
2025-06-13	PBYIPUMA BIOTECHNOLOGY, INC.S Sale	Director	SSale	−11.6K sh	$3.40	−$39.5K	75,390
2025-06-11	PBYIPUMA BIOTECHNOLOGY, INC.A Award	Director	AAward	+27K sh	—	—	87,000
2025-04-02	Verve Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,350 sh	$4.15	−$13.9K	13,280
2025-04-01	Verve Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+11.3K sh	—	—	16,630
2025-04-01	Verve Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−11.3K sh	—	—	33,750
2025-01-08	Verve Therapeutics, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+45K sh	—	—	45,000
2025-01-08	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2025-01-08	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+258K sh	—	—	258,000
2024-12-02	Verve Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−555 sh	$5.64	−$3,130.2	5,380
2024-11-29	Verve Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,875 sh	—	—	5,935
2024-11-29	Verve Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,875 sh	—	—	1,875
2024-06-18	PBYIPUMA BIOTECHNOLOGY, INC.A Award	Director	AAward	+27K sh	—	—	60,000
2024-06-13	PBYIPUMA BIOTECHNOLOGY, INC.S Sale	Director	SSale	−11K sh	$3.37	−$37.1K	33,000
2024-06-05	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2024-02-14	Verve Therapeutics, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+45K sh	—	—	45,000
2024-02-14	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+180K sh	—	—	180,000
2023-11-29	Verve Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,875 sh	—	—	4,614
2023-11-29	Verve Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,875 sh	—	—	3,750
2023-11-29	Verve Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−554 sh	$11.45	−$6,343.3	4,060
2023-06-13	PBYIPUMA BIOTECHNOLOGY, INC.A Award	Director	AAward	+27K sh	—	—	44,000
2023-06-13	PBYIPUMA BIOTECHNOLOGY, INC.S Sale	Director	SSale	−10K sh	$3.45	−$34.5K	17,000
2023-06-06	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2023-02-14	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+183K sh	—	—	182,800
2022-11-29	Verve Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−554 sh	$22.10	−$12.2K	2,186
2022-11-29	Verve Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,875 sh	—	—	5,625
2022-11-29	Verve Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,875 sh	—	—	2,740
2022-06-21	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2022-06-14	PBYIPUMA BIOTECHNOLOGY, INC.A Award	Director	AAward	+27K sh	—	—	27,000
2022-02-11	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+60K sh	—	—	60,000
2021-11-29	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+135K sh	—	—	135,000
2021-11-29	Verve Therapeutics, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+7,500 sh	—	—	7,500
2021-07-15	JBIOJade Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2021-07-15	PBYIPUMA BIOTECHNOLOGY, INC. · STOCK OPTION (RIGHT TO BUY)A Award	Director	AAward	+109K sh	—	—	108,721
2021-03-19	VYGRVoyager Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+30K sh	—	—	109,894
2021-02-16	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+68K sh	—	—	68,000
2021-02-16	VYGRVoyager Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+34K sh	—	—	79,894
2021-02-11	VYGRVoyager Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,186 sh	$7.55	−$24.1K	45,894
2021-01-12	VYGRVoyager Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,942 sh	$8.62	−$25.4K	49,080
2020-02-10	VYGRVoyager Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+27.5K sh	—	—	52,022
2020-02-10	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+55K sh	—	—	55,000
2020-01-21	VYGRVoyager Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,128 sh	$13.36	−$41.8K	24,522

Recent filings

Accepted (ET)
Jun 154
Dorval Allison0001437749-26-020703
SEC(opens sec.gov)
Jul 284
Dorval Allison0000950170-25-099262
SEC(opens sec.gov)
Jun 174
Dorval Allison0001437749-25-020713
SEC(opens sec.gov)
Jun 134
Dorval Allison0001437749-25-020360
SEC(opens sec.gov)
Apr 34
Dorval Allison0000950170-25-050559
SEC(opens sec.gov)
Jan 104
Dorval Allison0000950170-25-003855
SEC(opens sec.gov)
Dec 34
Dorval Allison0000950170-24-132799
SEC(opens sec.gov)

Companies

Address

C/O PUMA BIOTECHNOLOGY, INC. 10880 WILSHIRE BOULEVARD, SUITE 1700

LOS ANGELES, CA, 90024